Eleven Biotherapeutics (EBIO) vs. KemPharm (KMPH) Head-To-Head Analysis

Eleven Biotherapeutics (NASDAQ: EBIO) and KemPharm (NASDAQ:KMPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Volatility and Risk

Eleven Biotherapeutics has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500. Comparatively, KemPharm has a beta of -1.1, meaning that its stock price is 210% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Eleven Biotherapeutics and KemPharm, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eleven Biotherapeutics 0 0 0 0 N/A
KemPharm 0 0 4 0 3.00

KemPharm has a consensus target price of $9.00, indicating a potential upside of 143.24%. Given KemPharm’s higher probable upside, analysts clearly believe KemPharm is more favorable than Eleven Biotherapeutics.

Valuation & Earnings

This table compares Eleven Biotherapeutics and KemPharm’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eleven Biotherapeutics $29.98 million 0.96 $1.89 million ($1.06) -0.85
KemPharm N/A N/A -$16.51 million ($2.64) -1.40

Eleven Biotherapeutics has higher revenue and earnings than KemPharm. KemPharm is trading at a lower price-to-earnings ratio than Eleven Biotherapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Eleven Biotherapeutics and KemPharm’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eleven Biotherapeutics 11.28% -94.68% -29.28%
KemPharm N/A N/A -53.56%

Insider & Institutional Ownership

3.8% of Eleven Biotherapeutics shares are held by institutional investors. Comparatively, 36.0% of KemPharm shares are held by institutional investors. 28.7% of Eleven Biotherapeutics shares are held by insiders. Comparatively, 22.8% of KemPharm shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Eleven Biotherapeutics beats KemPharm on 7 of the 11 factors compared between the two stocks.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

KemPharm Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply